The study looked at people with a serious eye problem (retinal detachment) and found that those with weaker immune systems had worse surgery results. Adding a peptide called thymalin to the treatment helped many of the 17 patients recover better and had fewer complications. However, this was a small, very specific medical trial, not a general health guide.

Examination of the immunologic state of 73 patients with rhegmatogenous retinal detachment complicated by vitreoretinal proliferation has revealed correlation between the severity of the latter and disturbances in the immune state of the patient's body. 44% of patients with the stage C and 62% of patients with the stage D have immunodeficiency expressed by reduced level of T- and B-lymphocytes and their subpopulation. It is shown that disturbances in immunoreactivity can serve as an unfavourable sign for prognosis of effectiveness of surgical intervention in patients with rhegmatogenous retinal detachment. In 70% of the patients these disturbances lead to unfavourable outcome of the operation. For normalization of the revealed disturbances in the immune state, immunomodulator thymaline was used in a complex treatment of 17 patients. The preparation rose the effectiveness of the treatment in 78% of patients and reduced the number of postoperative complications. It is recommended to study the immunologic state of the patient with rhegmatogenous retinal detachment complicated by vitreoretinal proliferation for the purpose of its further correction and a higher effectiveness of surgical treatment of such patients.